Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Operating profit margin | = | 100 | × | Income (loss) from operations1 | ÷ | Revenue1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2020 | = | 100 | × | ÷ | |||
Dec 29, 2019 | = | 100 | × | ÷ | |||
Dec 30, 2018 | = | 100 | × | ÷ | |||
Dec 31, 2017 | = | 100 | × | ÷ | |||
Jan 1, 2017 | = | 100 | × | ÷ | |||
Jan 3, 2016 | = | 100 | × | ÷ | |||
Dec 28, 2014 | = | 100 | × | ÷ | |||
Dec 29, 2013 | = | 100 | × | ÷ | |||
Dec 30, 2012 | = | 100 | × | ÷ | |||
Jan 1, 2012 | = | 100 | × | ÷ | |||
Jan 2, 2011 | = | 100 | × | ÷ | |||
Jan 3, 2010 | = | 100 | × | ÷ | |||
Dec 28, 2008 | = | 100 | × | ÷ | |||
Dec 30, 2007 | = | 100 | × | ÷ | |||
Dec 31, 2006 | = | 100 | × | ÷ | |||
Jan 1, 2006 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$ in millions
The financial data reveals several notable trends over the analyzed periods regarding revenue, operating income, and operating profit margin.
- Revenue Growth
- Revenue exhibited a consistent upward trajectory from 2006 through 2019, increasing from $74 million to a peak of $3,543 million. The growth was particularly strong between 2008 and 2019, reflecting expanding sales or market penetration. However, in 2020, a decline is observed as revenue dropped to $3,239 million, suggesting a potential impact of external factors or market conditions affecting the fiscal year.
- Income (Loss) from Operations
- Operating income showed significant volatility in the initial years, with a large loss of $301 million in 2007 following positive results in 2006. Starting from 2008, income from operations generally improved and remained positive, with substantial growth evident by 2014, where it reached $515 million. This positive trend continued through 2019, peaking at $985 million. Yet, a decrease occurred in 2020, with operating income falling to $580 million, indicating challenges that impacted operational profitability.
- Operating Profit Margin
- The operating profit margin followed a similar pattern to operating income, initially negative or low in the early years (notably -82.12% in 2007) but showed steady improvement thereafter. From 2008 onwards, margins remained positive, fluctuating generally between approximately 17% and 28%. Highest margins were observed between 2014 and 2019, particularly around 27-28%, indicating efficient operational control during these years. However, a notable decline to 17.91% in 2020 corresponds with the reductions seen in revenue and operating income, possibly signaling reduced operational efficiency or increased costs.
Overall, the data signifies a growth phase marked by improving revenue and profitability metrics until 2019, followed by a downturn in 2020 that impacted both top-line and operational profit performance. This shift highlights the need for further investigation into the causes of the 2020 decline and consideration of strategies to restore growth and profitability levels.
Comparison to Competitors
Illumina Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|
Dec 31, 2020 | ||||||||
Dec 29, 2019 | ||||||||
Dec 30, 2018 | ||||||||
Dec 31, 2017 | ||||||||
Jan 1, 2017 | ||||||||
Jan 3, 2016 | ||||||||
Dec 28, 2014 | ||||||||
Dec 29, 2013 | ||||||||
Dec 30, 2012 | ||||||||
Jan 1, 2012 | ||||||||
Jan 2, 2011 | ||||||||
Jan 3, 2010 | ||||||||
Dec 28, 2008 | ||||||||
Dec 30, 2007 | ||||||||
Dec 31, 2006 | ||||||||
Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).